Rule-Based CAD of Digitized Mammograms

描述（由申请人提供）：鉴于乳房X线摄影术在早期识别乳腺癌中的重要性已得到公认和广泛接受，特别是在筛查中，近年来已开发并广泛研究了用于乳房X线摄影术的计算机辅助诊断（CAD）方案。某些CAD系统的诊断性能已达到临床实用性水平。然而，尽管做出了巨大的努力和重大的改进，CAD方案的性能水平，特别是与质量相关的性能水平，仍然不是最佳的。此外，它是越来越重要的探索方法，不仅要优化这些方案，而且要评估和比较它们的性能和鲁棒性时，在临床环境中使用。随着我们加大努力，在早期阶段发现异常，这一领域可能会在几个重要领域逐步取得进展。在这个项目中，我们建议继续进行各种研究，以改善和测试我们自己的几个CAD方案的性能和鲁棒性。我们还将评估多个图像（如多个视图或图像序列）可用并用于优化诊断检查结果时与系统性能相关的许多问题。我们将开发的许多方法和我们建议使用的技术，以优化性能，并确保这些计划的鲁棒性应适用于其他调查在这一领域和相关领域。最后，没有对不同集团（和公司）制定的计划进行直接比较，从而更好地了解不同办法的一些优点和局限性。我们建议在项目期间对大量活检证实的病例进行两次检查。

DESCRIPTION (provided by applicant): Given the recognized and widely accepted importance of mammography in early identification of breast cancer in general, and in screening, in particular, computer-aided diagnosis (CAD) schemes for mammography have been developed and investigated extensively in recent years. The diagnostic performance of some CAD systems is at the point where clinical utility has been demonstrated. However, despite significant efforts and major improvements, the performance level of CAD schemes, particularly as related to masses, remains less than optimal. In addition, it is becoming increasingly important to explore ways not only to optimize these schemes, but also to assess and compare their performance and robustness when used in the clinical environment. As we increase efforts to detect abnormalities at an earlier stage, this field is likely to progress incrementally in several important areas. In this project, we propose to continue to conduct a variety of studies to improve and test the performance and robustness of several of our own CAD schemes. We will also assess a number of issues associated with system's performance when multiple images, such as multiple views or sequences of images, are available and are used to optimize the results of a diagnostic examination. Many of the methods we will develop and the techniques we propose to use in order to optimize performance and assure robustness of these schemes should be applicable to other investigations in this and related fields. Last, there is no direct comparison of schemes developed by different groups (and companies) that will enable a better understanding of some of the advantages and limitations of different approaches. We propose to do so twice during the project on a large number of biopsy-proven cases.